FVE and FEEVA strongly advise the European Commission to extend its list of substances by including seven additional substances, seen the added clinical benefit given by these substances and the ANSES opinion on their safety. The seven substances are tenoic acid, phenylbutazone for systemic use and tetracaine, tetryzoline, synephrine, rifamycine, polymyxine B for ophthalmic use.